Cancer waiting times: Why additional capacity must support the whole pathway

New cancer waiting time data has brought renewed attention to one of the NHS's most important priorities: getting patients diagnosed and treated as quickly as possible.

In June 2026, 69.9% of patients in England began their first definitive cancer treatment within 62 days of an urgent referral.

The NHS has set a clear ambition for improvement. Under the 2026/27 planning framework, every Trust is expected to achieve 80% performance against the 62-day cancer standard by March 2027, alongside 94% for the 31-day treatment standard and maintaining the 80% Faster Diagnosis Standard.

The challenge now is translating those ambitions into additional capacity across already pressured pathways.

Cancer pathways are complex.

Increasing activity at one stage without sufficient capacity further along the pathway risks moving the bottleneck rather than removing it.

A patient may move through referral and diagnosis more quickly, for example, but still require access to specialist outpatient assessment, diagnostics, imaging, surgery or another treatment before their pathway can progress.

That's why sustainable cancer recovery requires a whole-pathway view.

Trusts need to understand where capacity constraints exist and ensure additional activity is targeted where it can have the greatest impact on patient flow.

For some pathways, surgery represents an important potential bottleneck.

Workforce availability, theatre capacity and competing elective pressures can all affect how quickly patients can access treatment once the decision to treat has been made. Clinically led insourcing can provide NHS organisations with flexible additional capacity, using existing NHS estate outside core operating hours to deliver additional activity alongside substantive teams. This can include additional theatre lists and specialist clinical teams, supported by operational management, governance and pathway coordination.

But simply adding another theatre list isn't enough.

Successful programmes need to consider pre-operative assessment, diagnostics, theatre utilisation, histology and pathology, follow-up requirements and the capacity available elsewhere in the patient's pathway.

The same principle applies across cancer services.

Depending on where local pressures exist, additional capacity may be needed across outpatient clinics, diagnostics and surgical services. An effective insourcing programme should therefore begin by understanding the individual service and its bottlenecks rather than applying a standard delivery model.

At Agile Insourcing, we work alongside NHS clinical and operational teams to understand those pressures and develop clinically led services around the needs of the pathway. Our multidisciplinary teams can support a range of specialties and services, with dedicated operational management, clinical governance and the flexibility to scale activity as priorities change.

There are already examples across the NHS demonstrating what can be achieved.

NHS organisations continue to improve pathways through greater diagnostic capacity, more direct referral routes, closer collaboration between primary and secondary care and redesigned models of delivery.The challenge is significant, but so is the determination across NHS services to improve access for patients.

Additional capacity can play an important role in supporting that work when it is deployed intelligently and integrated with existing services. Because ultimately, the objective isn't simply to deliver more activity.

Agile Insourcing works in partnership with NHS organisations to deliver clinically led outpatient, diagnostic and surgical capacity tailored around local service pressures.